Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients

被引:30
作者
Fathi, Zahra [1 ]
Mousavi, Seyed Ali Javad [2 ]
Roudi, Raheleh [3 ]
Ghazi, Farideh [1 ]
机构
[1] Iran Univ Med Sci, Dept Med Genet & Mol Biol, Fac Med, Tehran, Iran
[2] Iran Univ Med Sci, Minimally Invas Surg Res Ctr, Tehran, Iran
[3] Iran Univ Med Sci, Oncopathol Res Ctr, Tehran, Iran
来源
PLOS ONE | 2018年 / 13卷 / 07期
关键词
JOINT-CONSENSUS-RECOMMENDATION; POLYMERASE-CHAIN-REACTION; SEQUENCE VARIANTS; P53; CARCINOMA; EGFR; ADENOCARCINOMA; ASSOCIATION; EXPRESSION; BRAF;
D O I
10.1371/journal.pone.0200633
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose Lung cancer is the deadliest known cancer in the world, with the highest number of mutations in proto-oncogenes and tumor suppressor genes. Therefore, this study was conducted to determine the status of hotspot regions in DDR2 and KRAS genes for the first time, as well as in TP53 gene, in lung cancer patients within the Iranian population. Experimental design The mutations in exon 2 of KRAS, exon 18 of DDR2, and exons 5-6 of TP53 genes were screened in lung cancer samples, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) using PCR and sequencing techniques. Results Analysis of the KRAS gene showed only a G12C variation in one large cell carcinoma (LCC) patient, whereas variants were not found in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) cases. The Q808H variation in the DDR2 gene was detected in one SCC sample, while no variant was seen in the ADC and LCC subtypes. Variations in the TP53 gene were seen in all NSCLC subtypes, including six ADC (13.63%), seven SCC (15.9%) and two LCC (4.54%). Forty-eight variants were found in the TP53 gene. Of these, 15 variants were found in coding regions V147A, V157F, Q167Q, D186G, H193R, T211T, F212L and P222P, 33 variants in intronic regions rs1625895 (HGVS: c.672+62A>G), rs766856111 (HGVS: c.672+6G>A) and two new variants (c.560-12A>G and c.672+86T>C). Conclusions In conclusion, KRAS, DDR2, and TP53 variants were detected in 2%, 2.17% and 79.54% of all cases, respectively. The frequency of DDR2 mutation is nearly close to other studies, while KRAS and TP53 mutation frequencies are lower and higher than other populations, respectively. Three new putative pathogenic variants, for the first time, have been detected
引用
收藏
页数:17
相关论文
共 65 条
[1]   Epidemiology of lung cancer [J].
Alberg, AJ ;
Samet, JM .
CHEST, 2003, 123 (01) :21S-49S
[2]   Detecting lung cancer in plasma with the use of multiple genetic markers [J].
Andriani, F ;
Conte, D ;
Mastrangelo, T ;
Leon, M ;
Ratcliffe, C ;
Roz, L ;
Pelosi, G ;
Goldstraw, P ;
Sozzi, G ;
Pastorino, U .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) :91-96
[3]  
[Anonymous], ONCOTARGET
[4]  
[Anonymous], NEW NATIONWIDE GENOM
[5]   Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer [J].
Ashktorab, Hassan ;
Mokarram, Pooneh ;
Azimi, Hamed ;
Olumi, Hasti ;
Varma, Sudhir ;
Nickerson, Michael L. ;
Brim, Hassan .
ONCOTARGET, 2017, 8 (05) :7852-7866
[6]   Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma [J].
Bandoh, N ;
Hayashi, T ;
Kishibe, K ;
Takahara, M ;
Imada, M ;
Nonaka, S ;
Harabuchi, Y .
CANCER, 2002, 94 (07) :1968-1980
[7]   Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) [J].
Barlesi, Fabrice ;
Mazieres, Julien ;
Merlio, Jean-Philippe ;
Debieuvre, Didier ;
Mosser, Jean ;
Lena, Herve ;
Ouafik, L'Houcine ;
Besse, Benjamin ;
Rouquette, Isabelle ;
Westeel, Virginie ;
Escande, Fabienne ;
Monnet, Isabelle ;
Lemoine, Antoinette ;
Veillon, Remi ;
Blons, Helene ;
Audigier-Valette, Clarisse ;
Bringuier, Pierre-Paul ;
Lamy, Regine ;
Beau-Faller, Michele ;
Pujol, Jean-Louis ;
Sabourin, Jean-Christophe ;
Penault-Llorca, Frederique ;
Denis, Marc G. ;
Lantuejoul, Sylvie ;
Morin, Franck ;
Quan Tran ;
Missy, Pascale ;
Langlais, Alexandra ;
Milleron, Bernard ;
Cadranel, Jacques ;
Soria, Jean-Charles ;
Zalcman, Gerard .
LANCET, 2016, 387 (10026) :1415-1426
[8]   Why are there hotspot mutations in the TP53 gene in human cancers? [J].
Baugh, Evan H. ;
Ke, Hua ;
Levine, Arnold J. ;
Bonneau, Richard A. ;
Chan, Chang S. .
CELL DEATH AND DIFFERENTIATION, 2018, 25 (01) :154-160
[9]   Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy [J].
Chalela, Roberto ;
Curull, Victor ;
Enriquez, Cesar ;
Pijuan, Lara ;
Bellosillo, Beatriz ;
Gea, Joaquim .
JOURNAL OF THORACIC DISEASE, 2017, 9 (07) :2142-2158
[10]   Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations [J].
Chatziandreou, Ilenia ;
Tsioli, Panagiota ;
Sakellariou, Stratigoula ;
Mourkioti, Ioanna ;
Giannopoulou, Ioanna ;
Levidou, Georgia ;
Korkolopoulou, Penelope ;
Patsouris, Efstratios ;
Saetta, Angelica A. .
PLOS ONE, 2015, 10 (07)